This type or adaption (“structural breathing”) is most likely the reason why the Bcl-2 protein can bind various BH3 motifs of diverse Bcl-2 family members with high affinity, even if mutations in this binding pocket occur which dramatically reduce the affinity of rigid cancer drugs like venetoclax targeting this groove region31. The gene discussed is BCL2; the disease is cancer.